Idenix Pharmaceuticals Inc  

(Public, NASDAQ:IDIX)   Watch this stock  
Find more results for IDIX
24.50
Aug 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.93 - 24.50
Open     -
Vol / Avg. 0.00/1.99M
Mkt cap 3.71B
P/E     -
Div/yield     -
EPS -1.13
Shares 151.50M
Beta 0.27
Inst. own 79%
Oct 28, 2014
Q3 2014 Idenix Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Aug 4, 2014
Q2 2014 Idenix Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -26073.99%
Operating margin - -26379.53%
EBITD margin - -25181.88%
Return on average assets -122.90% -62.41%
Return on average equity -153.29% -75.22%
Employees 84 -
CDP Score - -

Address

320 Bent St
CAMBRIDGE, MA 02141-2025
United States - Map
+1-617-9959800 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.